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Although fasting induces hepatic triglyceride (TG) accumulation in both rodents and humans, little
is known about the underlying mechanism. Because parasympathetic nervous system activity tends
to attenuate the secretion of very-low-density-lipoprotein-triglyceride (VLDL-TG) and increase TG
stores in the liver, and serum cholinesterase activity is elevated in fatty liver disease, the inhibition
of the parasympathetic neurotransmitter acetylcholinesterase (AChE) may have some inﬂuence on
hepatic lipid metabolism. To assess the inﬂuence of AChE inhibition on lipid metabolism, the effect
of physostigmine, an AChE inhibitor, on fasting-induced increase in liver TG was investigated in
mice. In comparison with ad libitum-fed mice, 30 h fasting increased liver TG accumulation accom-
panied by a downregulation of sterol regulatory element-binding protein 1 (SREBP-1) and liver-fatty
acid binding-protein (L-FABP). Physostigmine promoted the 30 h fasting-induced increase in liver
TG levels in a dose-dependent manner, accompanied by a signiﬁcant fall in plasma insulin levels,
without a fall in plasma TG. Furthermore, physostigmine signiﬁcantly attenuated the fasting-
induced decrease of both mRNA and protein levels of SREBP-1 and L-FABP, and increased IRS-2 pro-
tein levels in the liver. The muscarinic receptor antagonist atropine blocked these effects of physo-
stigmine on liver TG, serum insulin, and hepatic protein levels of SREBP-1 and L-FABP. These results
demonstrate that AChE inhibition facilitated fasting-induced TG accumulation with up regulation of
the hepatic L-FABP and SREBP-1 in mice, at least in part via the activation of muscarinic acetylcho-
line receptors. Our studies highlight the crucial role of parasympathetic regulation in fasting-
induced TG accumulation, and may be an important source of information on the mechanism of
hepatic disorders of lipid metabolism.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mammals that often face starvation have evolved ingenious
metabolic systems. A key aspect of the adaptive response to foodshortage is the shift from carbohydrates to ketones as a primary
fuel source. In the fasting state, fatty acids are mobilized from adi-
pose tissue to the liver and oxidized to acetyl coenzyme-A, which is
a source of ketogenesis. Although the mechanisms are not fully
understood, 12–36 h of fasting can increase liver triglyceride (TG)
levels in both mice [1,2] and humans [3]. Hepatic steatosis, which
is the excessive accumulation of TG in the liver, is one of the risk
factors leading to the onset and progress of metabolic syndrome
and arteriosclerosis [4,5].
Hepatic steatosis is determined by balancing fatty acid (FA)
supply to the liver and intrahepatic lipogenesis with the rate of
b-oxidation and lipid export by the liver [6]. Liver fatty acid-bind-
ing protein (L-FABP; also known as FABP1), which represents a
large family of 15 kDa proteins capable of binding hydrophobic
lipid ligands, is an abundant protein expressed in hepatocytes
Fig. 1. Time course of fasting-induced liver TG accumulation in ICR mice. First we
validated the effects of fasting periods on the accumulation levels of hepatic TG in
8-week-old female ICR mice, because the TG accumulations to liver may be
different at a strain, sex, and week old of mice. At the 6-h, 12-h, 18-h 24-h, 30-h, 36-
h, or 48-h after the fasting respectively, the mice were sacriﬁced and collected a
piece of liver tissues. The extract from each animal liver tissue was measured by an
enzymatic colorimetric method. Values shown are the means ± S.E.M. of 4–11 mice.
⁄Signiﬁcant difference from ad libitum-fed mice (one-way ANOVA, Dunnett’s post
hoc test, P < 0.05).
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ﬁcking and metabolism, as L-FABP-deﬁcient mice exhibit resis-
tance to diet-induced steatosis and L-FABP deletion in
hepatocytes disrupts net FA uptake and utilization [9,10]. Sterol
regulatory element binding proteins (SREBP), which comprise
three isoforms, SREBP-1a, SERBP-1c, and SREBP-2, are synthesized
as 125 kDa precursors bound to endoplasmic reticulum mem-
brane, and are cleaved to generate soluble NH2-terminal fragments
(the mature form of 68 kDa) that translocate to the nucleus as
transcriptional regulators [4,11,12]. Although SREBP-1a and
SREBP-1c are produced from the same gene (SREBP-1) by alterna-
tive splicing, SREBP-1c is expressed more in tissues of high lipo-
genic capacity, such as liver and adipose tissue, than SREBP-1a.
SREBP-1c may be a pivotal transcriptional regulator of genes for
FA and TG synthesis, including fatty acid synthase (FAS) and acetyl
coenzyme-A carboxylase (ACC) [4,11,13]. Furthermore, it is
reported that SREBPs suppress insulin receptor substrate 2 (IRS-
2)-mediated hepatic insulin signaling [14], and may have an effect
on fatty acid oxidation via activating peroxisome proliferator acti-
vated receptor alpha (PPAR-a), peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC-1a), and Carnitine pal-
mitoyltransferase I (CPT1) [15,16]. In addition, phosphoenolpyr-
uvate carboxykinase (PEPCK), which is known to be a key
enzyme in gluconeogenesis, is necessary for the integration of
hepatic energy metabolism [17].
Many factors, including insulin resistance, altered lipogenic fac-
tors, lipotoxic free fatty acids, and biological stress, have been
implicated in the development of hepatic steatosis. Autonomic
nervous regulation is also a factor. It has long been known that
the sympathetic and parasympathetic nervous systems may
oppose or complement each other, but tend to balance each other
overall. In hepatic glucose metabolism, the activation of hepatic
sympathetic nerves increases blood glucose levels by stimulating
glycolysis, whereas the activation of hepatic parasympathetic
nerves represses hepatic glucose output by promoting glycogen
synthesis [18]. In hepatic lipid metabolism, the importance of sym-
pathetic drive has been attracting attention recently. Several stud-
ies consistently demonstrated that sympathetic activation
stimulates very-low-density-lipoprotein-triglyceride (VLDL-TG)
production and secretion from the liver into the blood circulation,
and increases blood TG levels [19–21]. A clinical study reported
that the predominance of sympathetic over parasympathetic activ-
ity is strongly associated with metabolic syndrome and might be
partly involved in unfavorable consequences such as the incidence
of cardiovascular disease [22]. Fasting beyond a certain period also
leads to a state of sympathetic nerve stimulation [21]. For example,
the ratio between low and high frequency components of heart
rate variability, that represents an index of sympathetic nerve
activity, was elevated under fasting conditions [23]. However,
few studies have examined the role of the parasympathetic ner-
vous system in hepatic lipid metabolism during fasting. Postpran-
dial plasma TG levels were increased by parasympathetic
denervation [20]. This has led to the assumption that the parasym-
pathetic nervous system tends to attenuate the secretion of VLDL-
TG from the liver and thus increases liver TG stores.
Inhibitors of acetylcholinesterase (AChE) are chemicals that
prevent AChE from breaking down the parasympathetic neuro-
transmitter acetylcholine (ACh), thereby promoting ACh activity.
Physostigmine (eserine), which is the oldest known AChE inhibitor,
is used clinically for the treatment of glaucoma and myasthenia
gravis, and as an antidote for atropine intoxication. It has attracted
some attention for its potential role in the amelioration of Alzhei-
mer’s disease [24,25]. Serum cholinesterase activity is elevated in
fatty liver diseases and has been accepted as a useful indicator in
the diagnosis of hepatobiliary diseases [26,27]. Although AChEinhibitors may also have some inﬂuence on lipid metabolism, to
our knowledge, few studies have attempted to clarify the effects
of AChE inhibitors on lipid metabolism under fasting conditions
where a sympathetic activity may dominate. In the present study,
we investigated the effect of the AChE inhibitor physostigmine on
the fasting-induced increase in liver TG in mice.
2. Results
2.1. Time course of fasting-induced liver TG accumulation in ICR mice
We ﬁrst validated the effects of fasting periods on the accumu-
lation levels of hepatic TG in ICR mice, because the TG accumula-
tion in the liver may vary with strain, sex, and age. Non-fasted
mice showed low TG levels (7.0 ± 5.46 mg/g liver; Fig. 1). Mice
fasted for 24 h and 30 h showed considerably high liver TG levels
(41.7 ± 6.84 and 33.6 ± 2.29 mg/g liver, respectively). In accordance
with the results, 30 h fasting, which stably induced hepatic TG
accumulation, was used for the following examinations.
2.2. Time course of plasma AChE activity and ACh concentration in
fasted and fed mice after the injection of physostigmine
We next validated the effects of physostigmine on plasma AChE
activity and ACh concentration in fasted and fed mice. The plasma
AChE activity decreased to 60% of the pre-injection (0 min) level at
30 min after the physostigmine injection, to 70% of the pre-injec-
tion level at 60 min, and to 90% of the pre-injection level at
60 min (Fig. 2A). Normal plasma AChE activity was restored at
240 min. There was no difference between fed and fasted mice.
The plasma ACh concentration of 53.9 ± 8.92 lM in ad libitum-
fed mice decreased to 31.9 ± 6.20 lM at 30 min after the physostig-
mine injection, and restored at 120 min (Fig. 2B). On the other
hand, the plasma ACh concentration of 40.6 ± 3.81 lM in 24 h-
fasted mice decreased to 31.9 ± 6.20 lM at 30 min after physostig-
mine injection, and restored at 120 min. In neither evaluation point
until 120 min after physostigmine injection, the signiﬁcant differ-
ence was detected between fed and fasted mice.
2.3. Effect of the AChE inhibitor physostigmine on the 30 h fasting-
induced increase in liver TG levels
As shown in Fig. 3A, 30 h fasting increased the liver TG in mice
compared with ad libitum-fed mice. Administration of the AChE
Fig. 2. Time course of plasma AChE activity and ACh concentration in fasted and fed
mice after the injection of physostigmine (0.3 mg/kg, s.c.). We validated the effects
of physostigmine on plasma AChE activity and ACh concentration in fasted and fed
mice. At the 24-h after the fasting (or ad libitum feeding), the mice were given a
subcutaneous (s.c.) injection of 0.3 mg/kg physostigmine. At each point, mice were
sacriﬁced and collected whole blood. The plasma specimen measured by the
ﬂuorometric enzyme assay for AChE or ACh. Values shown are the means ± S.E.M. of
4–12 mice. In neither evaluation point, the signiﬁcant difference was detected
between fed and fasted mice.
Fig. 3. Effect of AChE inhibitor physostigmine on liver TG (A) and plasma TG (B)
levels in the 30-h fasted mice. Mice underwent a 30-h fast from ZT6 (14:00) to ZT36
(the next day 20:00), and given a subcutaneous (s.c.) injection of physostigmine (0.1
or 0.3 mg/kg) or saline at ZT24 and ZT30. Muscarinic receptor antagonist atropine
(1 mg/kg, s.c.) was administered 15 min before the physostigmine injections. At the
30-h after the fasting, the mice were sacriﬁced and collected whole blood and a
piece of liver tissues. The plasma specimen and the extract from each animal liver
tissue were measured by an enzymatic colorimetric method, respectively. Values
shown are the means ± S.E.M. of 7–11 mice. ⁄Signiﬁcant difference from 30 h-fasted
mice with saline (described 0 mg/kg physostigmine in ﬁgure) (one-way ANOVA,
Dunnett’s post hoc test, P < 0.05). #Signiﬁcant difference between two groups
(Student’s t-test, P < 0.05).
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TG levels in a dose-dependent manner, and the increase was signif-
icantly different at a dose of 0.3 mg/kg once daily (semel in die,
SID; 47.6 ± 4.76 mg/g liver) or 0.3 mg/kg twice daily (bis in die,
BID; 54.2 ± 4.17 mg/g liver), whereas there was no difference in
the plasma TG levels between either group (Fig. 3B). The plasma
glucose level of 158.1 ± 4.32 mg/dL in ad libitum-fed mice
decreased to 45.4 ± 4.87 mg/dL in 30 h-fasted mice (Fig. 4A), while
the insulin concentration of 127.2 ± 30.43 pmol/L in ad libitum-fed
mice simultaneously decreased to 42.6 ± 6.16 pmol/L in 30 h-
fasted mice (Fig. 4B). Physostigmine additionally reduced the
30 h fasting-induced decrease in the plasma insulin concentration,
but raised the 30 h fasting-induced decrease in the plasma glucose
level. Signiﬁcant effects on the plasma glucose level and insulin
concentration were observed when physostigmine was adminis-
tered at 0.3 mg/kg, bis in die (BID) (86.4 ± 10.21 mg/dL and
19.1 ± 3.24 pmol/L, respectively). The muscarinic receptor antago-
nist atropine (1 mg/kg, BID) blocked the potentiating effect of phy-
sostigmine (0.3 mg/kg, BID) on the 30 h fasting-induced increase in
liver TG level, with a signiﬁcant increase in the plasma insulin con-
centration (liver TG, 34.0 ± 3.01 mg/g liver; plasma insulin,
31.2 ± 6.37 pmol/L). However, the plasma glucose level was not
restored by injection of atropine (1 mg/kg, BID). Treatment with
atropine alone during fasting failed to affect liver TG levels andplasma insulin concentrations, but increased plasma glucose
levels.
2.4. Effect of the AChE inhibitor physostigmine on the expression of
lipid-related genes in the liver
To characterize the effect of physostigmine on hepatic lipid
metabolism, we examined the expression of genes related to TG
synthesis (Srebp1c, Acc), b-oxidation of fatty acids (Ppara, Pgc1a,
Cpt1), gluconeogenesis (Pepck), FA trafﬁcking and metabolism
(Fabp1), and hepatic insulin signaling (Irs2). As reported previously
[8,26], gene expression of Srebp1c, Acc, and Fabp1 in the liver was
signiﬁcantly decreased in the 30 h-fasted mice compared with ad
libitum-fed mice (Fig. 5A–C), whereas Ppara, Pgc1a, Cpt1, and Irs2
were signiﬁcantly increased in the 30 h-fasted mice (Fig. 5D, F
and H). The liver mRNA levels of Fabp1 and Accwere higher in mice
administered physostigmine (0.3 mg/kg BID) than in fasting-only
mice, but did not exceed the mRNA levels in the liver of ad libi-
tum-fed mice. The effect of physostigmine on Fabp1 and Acc
expression in the liver was not changed by pre-injection of atro-
pine (1 mg/kg, BID). The liver mRNA levels of Pgc1a and Pepckwere
not affected by the 30 h of fasting (Fig. 5E and G). The liver mRNA
level of Pepck in mice pre-injected with atropine before physostig-
mine increased by more than twice the mRNA level in mice
injected with physostigmine only.
Fig. 4. Effect of AChE inhibitor physostigmine on plasma glucose (A) and plasma
insulin (B) in the 30-h fasted mice. Mice underwent a 30-h fast from ZT6 to ZT36,
and given a subcutaneous (s.c.) injection of physostigmine (0.1 or 0.3 mg/kg) or
saline at ZT24 and ZT30. The muscarinic receptor antagonist atropine (1 mg/kg, s.c.)
was administered 15 min before the physostigmine injections. At the 30-h after the
fasting, the mice were sacriﬁced and collected whole blood (as mentioned in
Section 2 and the legend of Fig. 3). Plasma glucose level and insulin concentration in
the specimen, which used for measurement of plasma TG levels in Fig. 3B, were
measured by a glucose dehydrogenase method and enzyme immunoassay, respec-
tively. Values shown are the means ± S.E.M. of 7–11 mice. ⁄Signiﬁcant difference
from 30 h-fasted mice with saline (described 0 mg/kg physostigmine in ﬁgure)
(one-way ANOVA, Dunnett’s post hoc test, P < 0.05). #Signiﬁcant difference between
two groups (Student’s t-test, P < 0.05).
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L-FABP and SREBP-1 in the liver
As mentioned above, physostigmine may have an inﬂuence on
TG synthesis-related genes and Fabp1. Therefore, we next analyzed
the protein expression levels of SREBP-1 and L-FABP in the liver. In
addition, we analyzed the 68 kDa protein equivalent to the mature
form of SREBP-1, similar to previous reports [11,12]. Fig. 6A shows
typical membrane immunoreactivity to anti-L-FABP, anti-SREBP-1,
and b-actin (as an internal control). The protein levels of L-FABP
and mature SREBP-1 in the liver were signiﬁcantly decreased in
the 30 h-fasted mice compared with ad libitum-fed mice (Fig. 6B
and C). Physostigmine (0.3 mg/kg, BID) increased the 30 h fast-
ing-induced relative protein levels of L-FABP and mature SREBP-
1, and the physostigmine-induced increase in both protein levels
was blocked by pre-injection of atropine (1 mg/kg, BID).2.6. Effect of physostigmine or atropine on the liver protein levels of L-
FABP and SREBP-1, liver TG, plasma TG, plasma glucose, and plasma
insulin in ad libitum-fed mice
As mentioned above, physostigmine may have facilitated fast-
ing-induced liver TG accumulation with up-regulation of hepatic
L-FABP and SREBP-1. On the other hand, treatment with atropine
alone during fasting signiﬁcantly increased plasma glucose levels
(Fig. 4). We have evaluated the effect of physostigmine or atropine
alone during ad libitum state on liver protein levels of L-FABP and
SREBP-1, liver TG, plasma TG, plasma glucose, and plasma insulin.
Fig. 7A shows typical membrane immunoreactivity to anti-L-FABP,
anti-SREBP-1, and b-actin. The protein levels of L-FABP and mature
SREBP-1 in the liver of ad libitum-fed mice were not inﬂuenced
neither by physostigmine nor by atropine (Fig. 7B and C). Neither
physostigmine nor atropine alone during fasting affected liver TG
level plasma TG, plasma glucose, and plasma insulin (Fig. 7D–G).
2.7. Effect of AChE inhibitor physostigmine on plasma glucagon,
plasma LDL/VLDL, and plasma FFA in fasted and fed mice
We also investigated the effect of physostigmine on plasma glu-
cagon, plasma LDL/VLDL, and plasma FFA in fasted and fed mice.
There were no signiﬁcant differences between fasted and fed mice
in plasma glucagon and plasma LDL/VLDL (Fig. 8A and B). Injection
of physostigmine also failed to affect in these parameters. On the
other hand, the plasma FFA level in 24 h-fasted mice was signiﬁ-
cantly higher than that in ad libitum fed mice (1.8 ± 0.11 mEq/L
and 1.2 ± 0.09 mEq/L, respectively) (Fig. 8C). At 30 h after fasting,
the plasma FFA in fasted mice decreased to 1.3 ± 0.10 mEq/L, but
that in mice with physostigmine maintained signiﬁcantly high
level (1.6 ± 0.07 mEq/L) in comparison to non-injected mice.
2.8. Effect of the AChE inhibitor physostigmine on the protein levels of
IRS-1 and IRS-2 in the liver
According to the experiments described above (Figs. 4 and 5),
physostigmine (0.3 mg/kg, BID) reduced plasma levels of insulin,
which is also a strong initiator of hepatic lipogenesis. Nevertheless,
physostigmine increased fasting-induced liver TG accumulation
and the expression of the Acc gene and mature SREBP-1 protein
in the liver. It has been reported that SREBPs directly bind to the
IRS-2 promoter and suppress IRS-2, leading to hepatic insulin resis-
tance [14,27]. Therefore, physostigmine might have an inﬂuence
on insulin sensitivity in the liver. In a previous report, we have
shown by Western blot analysis that dietary protein deprivation
increases the amount of insulin receptor b-subunit, IRS-1, and
IRS-2 [28]. As shown in Fig. 9, 30 h fasting increased the protein
levels of IRS-2. The 30 h fasting-induced increase in IRS-2 protein
levels was not inﬂuenced by the administration of physostigmine
alone, but was inﬂuenced by the combination of physostigmine
and atropine. In contrast, IRS-1 protein levels in the liver were
not inﬂuenced by fasting or drug administration.
3. Discussion
Because parasympathetic activity tends to attenuate the secre-
tion of VLDL-TG and increase the stores of TG in the liver [18,29],
and serum cholinesterase activity is elevated in human fatty liver
disease [31,32], AChE inhibitors may have some inﬂuence on hepa-
tic lipid metabolism. In the present study, administration of the
AChE inhibitor physostigmine did not induce the accumulation of
TG in normal liver from mice fed ad libitum, but did exacerbate
the accumulation of TG in the fatty liver caused by 30 h of fasting.
To our knowledge, this study is the ﬁrst report revealing that the
Fig. 5. Effect of AChE inhibitor physostigmine on the gene expression of L-Fabp (A), Srebp1c (B), Acc (C), Ppara (D), Pgc1a (E), Cpt1 (F) Pepck (G), and Irs2 (H) in liver extracts
from the 30-h fasted mice. Mice underwent a 30-h fast from ZT6 to ZT36, and given twice a day subcutaneous (s.c.) injection of 0.3 mg/kg physostigmine or saline at ZT24 and
ZT30. Muscarinic receptor antagonist atropine (1 mg/kg, s.c.) was administered 15 min before the physostigmine injections. At the 30-h after the fasting, the mice were
sacriﬁced and collected a piece of liver tissues. Total RNA was extracted from a piece of the liver tissues and performed PCR as described in Section 2. The relative levels of the
target gene PCR product were normalized to those of 18srRNA. Values shown are the means ± S.E.M. of 4–6 mice. ⁄Signiﬁcant difference from 30 h-fasted mice with saline
(described 0 mg/kg physostigmine in ﬁgure) (t-test or Wilcoxon–Mann–Whitney test, based on the F value, P < 0.05).
Fig. 6. Effect of AChE inhibitor physostigmine on the protein levels of L-FABP and SREBP-1 in liver extracts from the 30-h fasted mice. Mice underwent a 30-h fast from ZT6 to
ZT36, and given twice a day subcutaneous (s.c.) injection of 0.3 mg/kg physostigmine or saline at ZT24 and ZT30. Muscarinic receptor antagonist atropine (1 mg/kg, s.c.) was
administered 15 min before the physostigmine injections. At the 30-h after the fasting, the mice were sacriﬁced and collected a piece of liver tissues. The preparation of liver
extracts andWestern blot analyses was carried out as described in Section 2. The relative expression levels of the L-FABP and SREBP-1 proteins were normalized to those of b-
actin using same gels and membranes. (A) A representative immunoblot. (B) Quantiﬁcation of immunoreactivity of L-FABP. (C) Quantiﬁcation of immunoreactivity of SREBP-
1. Values shown are the means ± S.E.M. of 4–6 mice. ⁄Signiﬁcant difference from 30 h-fasted mice with saline (described 0 mg/kg physostigmine in ﬁgure) (t-test or
Wilcoxon–Mann–Whitney test, based on the F value, P < 0.05). #Signiﬁcant difference between two groups (Student’s t-test, P < 0.05).
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Fig. 7. Effect of physostigmine or atropine on the liver protein levels of L-FABP and SREBP-1 (A–C), liver TG (D), plasma TG (E), plasma glucose (F), and plasma insulin (G) in ad
libitum-fed mice. Mice were given twice a day subcutaneous (s.c.) injection of AChE inhibitor physostigmine (0.3 mg/kg; Phy), muscarinic receptor antagonist atropine (1 mg/
kg; Atro) or saline (5 mL/kg; V) at ZT0 and ZT6. Mice were sacriﬁced and collected a piece of liver tissues and whole blood at ZT12. All of the analyses were carried out as
mentioned above. Values shown are the means ± S.E.M. of 4–8 mice. The signiﬁcant difference was not detected.
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TG accumulation.
During fasting, it is thought that sympathetic activity is
increased in most peripheral tissues [21], and that parasympa-
thetic activity is reduced concomitantly. At least in our experimen-
tal conditions, the plasma ACh level in 30 h-fasted mice was not
signiﬁcantly different from that in ad libitum-fed mice, but slightly
lower than that in ad libitum-fed mice. Sympathetic nerve signals
are transmitted to each organ involved in TG metabolism. This
increases FFA secretion from white adipose tissue and promotes
VLDL-TG production and secretion from liver leading to elevatedblood TG levels. Injecting an AChE inhibitor might restore the
activity of parasympathetic nerves weakened during fasting. There
is also the possibility that, while fasting stimulates the sympathetic
nervous system and increases FFA secretion from white adipose
tissue to the blood circulation, physostigmine retains hepatic para-
sympathetic activity and keeps TG in the liver. In the present
experiment, physostigmine signiﬁcantly increased hepatic expres-
sion level of FA trafﬁcking protein L-FABP in 30 h-fasted mouse.
The effect of the physostigmine contributing to fasting-induced
liver TG accumulation might be relatively high, because plasma
FFA as an important source was signiﬁcantly higher in physostig-
Fig. 8. Effect of AChE inhibitor physostigmine on plasma glucagon (A), plasma LDL/VLDL (B), and plasma FFA (C) in fasted and fed mice. Mice underwent a 30-h fast from ZT6
to ZT36, and given twice a day subcutaneous (s.c.) injection of 0.3 mg/kg physostigmine or saline at ZT24 and ZT30. Muscarinic receptor antagonist atropine (1 mg/kg, s.c.)
were administered 15 min before the physostigmine injections. To examine the effect of fasting duration, we also measured the plasma FFA concentration in 24 h-fasted mice.
At the 30-h or 24-h after the fasting, the mice were sacriﬁced and collected whole blood. The plasma specimen measured by the ﬂuorometric or colorimetric enzyme assay kit
for glucagon, LDL/VLDL, or FFA, respectively. Values shown are the means ± S.E.M. of 6–16 mice. ⁄Signiﬁcant difference from ad lib-fed mice (t-test, P < 0.05). #Signiﬁcant
difference between two groups (t-test, P < 0.05).
Fig. 9. Effect of AChE inhibitor physostigmine on the protein levels of IRS-1 and IRS-
2 in liver extracts from the 30-h fasted mice. Mice underwent a 30-h fast from ZT6
to ZT36, and given twice a day subcutaneous (s.c.) injection of 0.3 mg/kg
physostigmine or saline at ZT24 and ZT30. Muscarinic receptor antagonist atropine
(1 mg/kg, s.c.) and recombinant human insulin (1 U/kg, i.p.) were administered
15 min before the physostigmine injections. At the 30-h after the fasting, the mice
were sacriﬁced and collected a piece of liver tissues. The preparation of liver
extracts and Western blot analyses was carried out as described in Section 2. A
representative immunoblot was shown.
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adipose tissue is high and LDL/VLDL secretion from liver is kept
constant, the up-regulation of FFA incorporation to the liver during
fasting might be likely to facilitate TG accumulation.
Physostigmine-induced increase in liver TG accumulation dur-
ing fasting was clearly blocked by atropine, an antagonist of mus-
carinic ACh receptors. In addition, we found a clue to the molecular
mechanisms of hepatic TG accumulation; physostigmine up regu-
lated the expression of L-FABP and mature SREBP-1 accompanied
by TG accumulation in the liver. This result suggests that the acti-
vation of parasympathetic nerves stimulates TG synthesis in fatty
liver by the maturation of SREBP-1, a transcriptional regulator.
Parasympathetic nerve activation also facilitates the incorporation
of FA, which is mobilized from adipose tissues during fasting, intothe liver by increasing L-FABP expression. The protein levels of L-
FABP and mature SREBP-1 was blocked by atropine, a muscarinic
receptor antagonist. Moreover, atropine attenuated both the phy-
sostigmine-induced increase in liver TG accumulation and
decrease in plasma insulin concentration. These results suggest
that physostigmine directly stimulates L-FABP expression and
SREBP-1 activation in the fatty liver, at least in part through the
muscarinic ACh receptors. However, current experiments do not
allow conclusions about the degree of lipogenesis effectively
occurring within the tissue. The use of radioactive precursors
(water or acetate) would allow for a direct assessment of hepatic
de novo fatty acid- or triglyceride synthesis. Therefor future exper-
iment would help determine whether the degree of fatty acid
uptake is affected.
In the present study, the administration of atropine (1 mg/kg,
BID) alone to mice fed ad libitum did not alter liver or plasma TG
levels. Furthermore, atropine alone neither aggravated nor amelio-
rated the accumulation of TG in the liver after 30 h of fasting. Atro-
pine inhibited the decrease in plasma glucose caused by fasting,
but did not inhibit the effect of physostigmine on the fasting-
induced decrease in plasma glucose levels. There is a possibility
that atropine exerts a positive action on systemic lipid metabolism
as well as on the antagonistic action on physostigmine. Although
the target tissue of atropine remains unclear, it is suggested that
tissues involved in glucose homeostasis, i.e. pancreas, fat cells,
and/or intestine, but not liver, are critical candidates. Atropine acts
on muscarinic receptors only, while physostigmine acts on both
muscarinic and nicotinic receptors. In general, 0.3 mg/kg dose of
physostigmine is extremely high dose, which cannot assume clin-
ical application for human. However in mouse and rat, 0.3 mg/kg
dose is often used in experiment, which clearly exerts drug efﬁcacy
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the effects of physostigmine, which were not blocked by atropine,
may be exerted via activation of nicotinic receptors.
Our previous reports showed that dietary glucose deprivation
promoted the effect of insulin on glucose uptake in the muscle
and inhibited gluconeogenesis by the enhancement of insulin sig-
nals through the IR–IRS–PI3K pathway in the liver [28,30]. This
suggests that the decrease in glucose content and availability pro-
motes tissue-speciﬁc insulin sensitivity as an adaptive response to
a critical situation. In the present study, the amount of IRS-2 in the
liver increased in 30 h-fasted mice, indicating the possibility that
fasting itself increases the amount of the insulin signaling mole-
cule in the mouse liver, which could enhance insulin action. In
the present study, physostigmine did not affect IRS-2 mRNA
expression and IRS-2 protein levels in fatty liver. This suggests that
the effect of physostigmine is not directly concerned with IRS-2
related signaling pathway in the liver. On the other hand, the
expression of IRS-2 in the liver seems to be increased by an addi-
tional atropine injection. The increase in protein levels of L-FABP
and SREBP-1 in the liver was clearly blocked by atropine, whereas
atropine injection was ineffective on the physostigmine-induced
increase in mRNA expression, such as Fabp1, Acc, and Irs2. The rea-
son is unclear why there is no correlation between mRNA expres-
sion and protein levels. There is a possibility that physostigmine
effects on not only the liver muscarinic ACh receptors but also
other plural complicated targets and/or metabolic pathways. Alter-
nately, the expression time course may not be identical between
mRNA expression and protein levels. It has been reported that in
the isolated rat liver, ACh increases glucose production from the
liver and enhances glycogen synthesis [33], whereas in white adi-
pose tissues, ACh attenuates insulin-stimulated glucose uptake and
the release of glycerol from adipocytes [29]. The mechanism
underlying the effect of parasympathetic agents is unclear. How-
ever, it is assumed that the alteration of tissue-speciﬁc insulin sen-
sitivity is at least partially involved in the stimulatory effect of
physostigmine on the 30 h fasting-induced increase in TG levels
in the mouse liver. Further investigation into TG metabolism in
adipose tissue is required to clarify the systemic effect of physo-
stigmine on lipolysis in adipose tissue and characterize the role
of parasympathetic regulation in hepatic lipid disorders.
We initially hypothesized that parasympathetic activation by
physostigmine has effects on the pancreas and augments insulin
secretion. This hypothesis was based on evidence from various ani-
mal models showing that increased parasympathetic input to the
pancreas contributes to hyperinsulinemia, which is independent
of blood glucose levels [34]. In the present study, physostigmine
promoted the decrease in plasma insulin concentrations caused
by 30 h of fasting, but restored the fasting-induced decrease in
plasma glucose levels. Our data demonstrated that atropine and
physostigmine did not alter plasma insulin levels in ad libitum-
fed mice. Furthermore, one of the opposite or contrasting hor-
mones glucagon, which is produced from pancreatic alpha-cells
and signals the liver to break down glycogen stores, was also not
altered by atropine and physostigmine. Although the mechanisms
contributing to this contradictory effect of physostigmine on insu-
lin-producing pancreatic beta-cells remains unknown, it is sug-
gested that the target organ of physostigmine in the present
experiment is not the pancreas.
When mice were fed ad libitum, the secretion of incretins,
which are gastrointestinal hormones including gastric inhibitory
peptide and glucagon-like peptide-1, is promoted by the physical
stimulation of food intake [35,36]. Because incretins are also con-
trolled by the parasympathetic nervous system, the restoration of
parasympathetic activity by physostigmine might stimulate the
secretion of incretins resulting in the insulin-dependent accumula-
tion of lipids. Furthermore, inhibition of AChE may also haveeffects unrelated to the parasympathetic system, i.e., ghrelin is
activated during fasting and degraded by ACh.
In the present study, the levels of Ppara, Pgc1a, and Cpt1, the
genes associated with b-oxidation of FA, were not signiﬁcantly
inﬂuenced by physostigmine injection to fasted mice, although
Pgc1a was not also inﬂuenced by 30-h fasting alone. This result
suggests that physostigmine has no discernible effect on hepatic
b-oxidation. On the other hand, it is reported that SREBP-1
promotes the transcription of TG synthesis genes and stimulates
b-oxidation of FA through the direct activation of PPAR-a and
PGC-1a [15,16]. Mature SREBP-1 protein, which is increased in
the liver by physostigmine administration, may inﬂuence hepatic
b-oxidation and TG synthesis. Further investigation is required to
clarify the effect of physostigmine on hepatic b-oxidation.
In conclusion, this study demonstrated that AChE inhibition
aggravated fasting-induced acute TG accumulation with up regu-
lation of hepatic L-FABP and SREBP-1 in mice, at least in part via
activation of the muscarinic ACh receptors, although at present it
is unclear whether next to the liver other organs are involved in
this TG accumulation promoting effect of AChE inhibition. Our
studies highlight the critical role of parasympathetic regulation
in fasting-induced TG accumulation, and may be an important
source of information on the mechanism of hepatic lipid
disorders.4. Materials and methods
4.1. Animals and experimental protocols
Eight-week-old female ICR mice (Tokyo Laboratory Animals,
Tokyo, Japan) were housed at 22 ± 2 C in an atmosphere with a
humidity of 60 ± 5%, subjected to a 12 h light/12 h dark cycle,
and provided with food and water ad libitum before the experi-
ments. The lights-on time was 8:00 and was assigned Zeitgeber
time (ZT) 0. Experimental animal care was conducted with permis-
sion from the Committee for Animal Experimentation of the School
of Science and Engineering at Waseda University. All drugs were
freshly prepared before injection. In the experiments, mice under-
went a 30 h fast from ZT6 (14:00) to ZT36 (20:00 the next day), and
given a subcutaneous (s.c.) injection of physostigmine (0.1 or
0.3 mg/kg) or saline at ZT24 and ZT30. The muscarinic receptor
antagonist atropine (1 mg/kg, s.c.) was administered 15 min before
the physostigmine injections. At 30 h after fasting, the mice were
anesthetized with ether and sacriﬁced, and whole blood and liver
tissue samples were collected. An assay for liver TG levels was per-
formed as described previously [37,38]. Each blood sample was
centrifuged to obtain plasma, and a plasma specimen from each
animal was used to calculate ACh concentration using Choline/Ace-
tylcholine Quantiﬁcation Colorimetric/Fluorometric Kit (BioVision,
CA, USA), AChE activity using Acetylcholinesterase Activity Colori-
metric Assay Kit (BioVision, CA, USA), TG concentration using Tri-
glyceride E-test Wako (Wako Pure Chemical Industries, Osaka,
Japan), glucose concentration using Glucose Pilot (Aventir Biotech,
Carlsbad, CA), insulin concentration using Mouse Insulin ELISA
(Mercodia AB, Sylveniusgatan, Sweden), glucagon concentration
using Mercodia Glucagon ELISA (Mercodia AB, Sylveniusgatan,
Sweden), LDL/VLDL concentration using HDL and LDL/VLDL Quan-
tiﬁcation Colorimetric/Fluorometric Kit (BioVision, CA, USA), and
FFA concentration using NEFA C-test Wako (Wako Pure Chemical
Industries, Osaka, Japan).
4.2. Real-time quantitative PCR analysis
A liver sample from each animal was dissolved in RNA-Solv
Reagent (Omega Bio-Tek, Norcross, GA), and total RNA was
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ciﬁc primer pairs were designed based on published data for the
18srRNA, Srebp-1c, L-Fabp, Irs2, Acc, Fas, Pgc-1a, and Pepck genes
[37–39]. The relative levels of the target gene PCR product were
normalized to those of 18srRNA. Data were analyzed by the
delta-delta Ct method. Melt curve analysis was performed to check
for nonspeciﬁc products. The results indicated no ampliﬁcation of
nonspeciﬁc products.
4.3. Western blot analysis
Anti-SREBP-1 antibody (sc-8984), anti-IRS-1 antibody (sc-559),
and anti-IRS-2 antibody (sc-8299) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-L-FABP antibody (#5352) was
purchased from Cell Signaling Technology (Danvers, MA). Anti-b-
actin antibody (#622102; Poly6221) was purchased from BioLeg-
end (San Diego, CA). The preparation of liver extracts and Western
blot analyses were carried out according to a slight modiﬁcation of
methods described previously [11,40]. The blotted signals were
visualized using LAS-4000 UVmini systems (Fujiﬁlm, Tokyo, Japan)
and signal intensity was analyzed densitometrically (Multi Gauge
V3.0; Fujiﬁlm, Tokyo, Japan). The relative expression levels of the
L-FABP and SREBP-1 proteins were normalized to those of b-actin
using same gels and membranes. The ﬁrst blot used anti-L-FABP
or anti-SREBP-1 antibody was stripped by conventional methods,
and then provided for b-actin evaluations.
4.4. Data analysis
All data are expressed as means ± standard error of the mean
(S.E.M.). One-way analysis of variance (ANOVA) followed by the
Dunnett’s test were used for intragroup comparisons of the physo-
stigmine dose-dependency and fasting period-dependency. For the
other comparisons between two different groups, the data were
assessed by ANOVA. Depending on the F value, either the Student’s
t-test or the Wilcoxon–Mann–Whitney test was used to determine
statistical signiﬁcance. Differences were considered signiﬁcant
when P < 0.05.
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